Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Government needs...

    Government needs proactive approach to boost pharma sector: Industry

    Written by Ruby Khatun Khatun Published On 2017-12-02T10:15:16+05:30  |  Updated On 2021-08-18T14:36:02+05:30

    MUMBAI: Union and state governments need to develop a proactive approach towards building better quality compliance and become a facilitator of funds and platforms, leaving the mechanism of delivery to the private sector to help the pharma sector grow faster, according to industry experts.


    The Indian pharmaceutical industry, with the current market size of USD 27.57 billion is expected to reach USD 55 billion by 2020 growing at a CAGR of 15.92 percent.

    "We have to strengthen and define the government and the private sector's role in developing the industry. The government needs to act as the provider and the private sector should deliver," industry veteran and Salus Lifesciences director Kewal Handa at 'CPhI CEO Roundtable Conference' here.

    The government has shown willingness to collaborate with the industry to create a favourable ecosystem for the sector, Handa said.


    Industry leaders discussed vital issues of Make in India - ensuring country's pharma supremacy with a special focus on affordable healthcare in the urban and rural areas.

    While India ranks amongst the top four pharma terms of volume of produced drugs, certain challenges continue to surround its pharma industry.

    India faces issues including a time-consuming approval process, dependence on China for cheaper API sources, sub-optimal infrastructure, lack of funding avenues, and a shortage of highly skilled talent, among others, UBM India managing director, Yogesh Mudras said.

    The US - the largest importer of Indian generics -- has started looking inwards at its own domestic market, Mudras pointed out.

    "There are quite a few issues that all the sector and the industry should accept existing challenges and find ways to change the ecosystem," EY partner Sriram Shrinivasan said.

    Speaking on the occasion, Indian Pharmaceutical Alliance secretary general DG Shah said, for 'Make in India', certain standards need to be set. It needs to take the initial steps and gain the confidence of the regulators and also understand that the industry culture and behavior are inter-linked.

    The pharma industry has grown at an exponential rate and people have moved in the hierarchy, unfortunately without acquiring the requisite skill sets.

    Thus, an emphasis of the industry should be on people management along with controlling the quality of the product output, he said.
    API Boost compliance DG Shah government India indian pharma news Indian Pharmaceutical Alliance Indian pharmaceutical industry industry Kewal Handa Pharma Industry pharma news pharma news india pharma sector proactive approach Quality Salus Lifesciences Sriram Shrinivasan UBM India Yogesh Mudras 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X